Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The prescriber base has doubled for Trogarzo

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Apr 14, 2021 9:30am

92 Views

Post# 32991734

RE:RE:The prescriber base has doubled for Trogarzo

Doubled from when to when? We know at one point Egrifta sales dropped off a cliff during the switch from f4 to SV, if he's cherry-picked that moment as the start point then shame on him. I don't see how actual sales support a prescription doubling.

SPCEO1 wrote: It was a fun fact to report but apparently it has no actual meaning since sales certainly did not more than double too. It is not hard to have a negative take on that piece of info - prescribers more than doubled but sales went nowhere so, that suggests the older prescribers were prescribing quite a bit less.

palinc2000 wrote: Did I hear that correctly?